Abstract
Examine pharmacoeconomics and health outcomes budgets, structures and strategies:
With ever-increasing pressures from managed care organizations, government
agencies, pharmacy benefit managers and other reimbursement groups for
pharmaceutical companies to prove their products' value, pharmacoeconomics is
a becoming a more and more important science. Empowered and well-funded health
outcomes groups can help pharma companies earn their way on to tough-to-crack
formularies, justify premium pricing, and provide convincing data for sales
forces influencing prescribers. These groups can also inform early research
termination decisions, help judge partnership opportunities and much more.
Pharmacoeconomics and Health Outcomes: Driving Formulary Access and
Reimbursement examines the inner workings of pharmacoeconomics and health
outcomes functions. From structures and communication links to budget amounts
and control to departmental staffing levels, the report details the strategies
of some of the industry' s top pharmacoeconomics groups.
The information contained within this report is gathered from numerous global
pharmacoeconomics and health outcomes directors, associate directors and
leaders. From phase- by-phase brand-level pharmacoeconomics spending to
resource allocation, this report guides health outcomes groups to greater
success.
This report is divided into 9 chapters. The first 8 chapters profile each
participating company' s pharmacoeconomics/health outcomes department. The last
chapter provides comparisons across all of the examined groups.
View Cart
